Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.
Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:
BHP Group Ltd (ASX: BHP)
According to a note out of Morgans, its analysts have retained their add rating on this mining giant's shares with an improved price target of $49.70. The broker has been looking at large cap miners following recent quarterly updates. BHP remains one of its top picks, particularly given its strong balance sheet. And while Morgans is cautious on iron ore prices, it remains positive and sees the miner as one of the safest options out there in the sector. Another reason to be positive is that the broker believes BHP will reward shareholders with a larger than expected interim dividend next week. The BHP share price is trading at $40.04 on Wednesday.
Breville Group Ltd (ASX: BRG)
A note out of Macquarie reveals that its analysts have retained their outperform rating and lifted their price target on this appliance manufacturer's shares to $41.10. This follows the release of a strong half year result earlier this week, which was in line with the broker's expectations. Macquarie was particularly pleased with new product launches, its expansion into China, and management's decision to increase its inventory in the United States to lessen the impact of tariffs on its near term earnings. Overall, the broker believes that Breville is well-placed to deliver earnings at the top end of its guidance range in FY 2025. The Breville share price is fetching $36.33 at the time of writing.
CSL Ltd (ASX: CSL)
Analysts at Goldman Sachs have reaffirmed their buy rating on this biotechnology giant's shares with a trimmed price target of $318.40. According to the note, the broker felt that CSL delivered a mixed half year result this week. It notes that its strong immunoglobulin growth and solid gross margin improvements in the CSL Behring business was overshadowed by weakness across its Seqirus influenza vaccines segment. However, given the importance of the CSL Behring business, the broker believes investors should be focusing on its improvements and is confident that the company will deliver on its annual double-digit earnings growth target over the medium term. The CSL share price is trading at $254.41 this afternoon.
